| 1347 |
National Cancer Institute |
Html |
null |
Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of pancreatic neuroendocrine tumors (islet cell tumors). |
|
|
CLICK HERE |
| 1352 |
National Cancer Institute |
Html |
en |
Bladder Cancer Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of bladder cancer. |
| bladder infections | 0.409188 |
| cancer spreads | 0.362526 |
| body | 0.421643 |
| type | 0.363946 |
| transitional cell carcinoma | 0.368057 |
| Partial cystectomy | 0.367914 |
| following PDQ summaries | 0.361033 |
| PDQ cancer information | 0.437047 |
| cancer increases | 0.35829 |
| clinical trial search | 0.428286 |
| bladder cancer | 0.996648 |
| clinical trials | 0.716737 |
| stage IV bladder | 0.400568 |
| cancer information summary | 0.412718 |
| clinical trial | 0.562865 |
| Institute about bladder | 0.388854 |
| breast cancer prevention | 0.364729 |
| superficial bladder cancer | 0.471082 |
| patients | 0.385176 |
| treatment clinical trial | 0.370642 |
| PDQ Adult Treatment | 0.359776 |
| NCI PDQ cancer | 0.382156 |
| lymph nodes | 0.358627 |
| radiation therapy | 0.477016 |
| Treatment Editorial Board | 0.366853 |
|
| metastatic bladder cancer | 0.451959 |
| General information | 0.370997 |
| general cancer information | 0.374576 |
| treatment | 0.542299 |
| cancer prevention | 0.364857 |
| new cancer treatments | 0.373348 |
| Recurrent bladder cancer | 0.48553 |
| NCI-supported cancer | 0.389073 |
| Cancer Information Service | 0.375145 |
| urinary diversion | 0.368656 |
| invasive bladder cancer | 0.467339 |
| treatment clinical trials | 0.395244 |
| National Cancer Institute | 0.448421 |
| radical cystectomy | 0.396674 |
| new treatment | 0.433088 |
| External radiation therapy | 0.441508 |
| Bladder Cancer Treatment | 0.456321 |
| Cancer Care page | 0.36454 |
| Blood. The cancer | 0.364373 |
| bladder cancer cells | 0.466875 |
| cancer research process | 0.367381 |
| cancer clinical trials | 0.446025 |
| cancer information summaries | 0.373713 |
| comprehensive cancer information | 0.373405 |
|
CLICK HERE |
| 1381 |
National Cancer Institute |
Html |
en |
Skin Cancer Prevention (PDQ®)–Health Professional Version |
Expert-reviewed information summary about factors that may influence the risk of developing skin cancer and about research aimed at the prevention of this disease. |
| skin cancer | 0.822138 |
| NMSC lesion reduction | 0.586326 |
| skin cancer reduction | 0.555393 |
| self-reported midday sun | 0.540371 |
| average new lesions | 0.584312 |
| Skin Cancer Prevention | 0.571287 |
| study attrition rates | 0.542607 |
| new actinic keratoses | 0.584773 |
| fewer actinic lesions | 0.603501 |
| skin cancer—a time | 0.536376 |
| daily sunscreen application | 0.747804 |
| poor surrogate endpoint | 0.539998 |
| 6-month post-intervention follow-up | 0.542973 |
| fewer new lesions | 0.602501 |
| solar keratoses | 0.994656 |
| provider-based sun protection | 0.532584 |
| sun protection factor | 0.548485 |
| Australian randomized study | 0.58712 |
| regular sunscreen | 0.624027 |
| sunscreen placebo | 0.612947 |
| UV radiation exposure | 0.5401 |
| clinically normal skin. | 0.54962 |
| SCC prevention trials | 0.561668 |
|
| new solar keratoses | 0.591696 |
| sun-protective behaviors | 0.556779 |
| significantly lower number | 0.53979 |
| chemopreventive agent | 0.53119 |
| invasive skin cancer | 0.584968 |
| community skin cancer | 0.550184 |
| population-based longitudinal study | 0.568978 |
| significantly greater number | 0.537464 |
| placebo group | 0.679758 |
| NMSC incidence rates | 0.595744 |
| Reduce Actinic Cancer | 0.56707 |
| spontaneous regression rate | 0.544682 |
| 4-month clinical trials | 0.540996 |
| randomized controlled trial | 0.576053 |
| new lesions | 0.702948 |
| randomized trials | 0.539994 |
| nicotinamide group | 0.630321 |
| base-cream placebo group | 0.599568 |
| appearance-based behavioral interventions | 0.531285 |
| sun exposure | 0.594318 |
| sunscreen group | 0.779335 |
| NMSC lesions | 0.609075 |
| self-reported sun-protective behaviors | 0.541953 |
|
CLICK HERE |
| 1427 |
National Cancer Institute |
Html |
en |
Cancer Pain (PDQ®)–Patient Version |
Expert-reviewed information summary about pain as a complication of cancer or its treatment. Approaches to the management and treatment of cancer-associated pain are discussed. |
| pain pathway | 0.562753 |
| cancer treatment | 0.530419 |
| opioid doses | 0.512563 |
| certain older patients | 0.494486 |
| blocks pain | 0.560936 |
| PDQ cancer information | 0.578981 |
| Skin pain | 0.59257 |
| pain medicine | 0.620891 |
| pain treatment | 0.60597 |
| different opioid | 0.496343 |
| pain control plan | 0.622009 |
| means mild pain | 0.593227 |
| cancer information summary | 0.53585 |
| bone pain | 0.598741 |
| PDQ Cancer Pain | 0.631355 |
| patients | 0.72567 |
| cancer patients | 0.497501 |
| Poor pain | 0.553511 |
| NCI PDQ cancer | 0.498652 |
| effects | 0.513118 |
| radiation therapy | 0.594681 |
| patients better pain | 0.603263 |
| chronic pain | 0.55423 |
| pain control medicine | 0.611052 |
| new pain | 0.590569 |
|
| breakthrough pain | 0.577542 |
| palliative care | 0.539853 |
| Pain relievers | 0.575317 |
| pain control | 0.678976 |
| Treating Cancer Pain | 0.619773 |
| National Cancer Institute | 0.532557 |
| commonly used opioid | 0.491401 |
| pain relief | 0.639394 |
| cancer pain | 0.765349 |
| older patients | 0.709433 |
| pain | 0.970646 |
| current pain treatments | 0.604816 |
| healthcare team | 0.547409 |
| drugs | 0.511492 |
| opioid treatment | 0.49086 |
| external radiation therapy | 0.506549 |
| intense pain | 0.577346 |
| severe pain | 0.654451 |
| PDQ summary | 0.540695 |
| control pain | 0.601004 |
| pain levels | 0.579761 |
| means moderate pain | 0.593293 |
| pain threshold | 0.556519 |
| means severe pain | 0.59891 |
|
CLICK HERE |
| 1605 |
National Cancer Institute |
Html |
en |
Cervical Cancer Screening (PDQ®)–Patient Version |
Expert-reviewed information summary about tests used to detect or screen for cervical cancer. |
| PDQ Screening | 0.389933 |
| abnormal cells | 0.425615 |
| helpful screening test | 0.401855 |
| treatment | 0.366742 |
| cancer screening methods | 0.422407 |
| Pap test results | 0.472434 |
| ongoing clinical trials | 0.410435 |
| certain positive Pap | 0.459229 |
| screening tests | 0.370134 |
| cervical cancer increases | 0.4511 |
| HPV test lowers | 0.401961 |
| cancer cells | 0.382684 |
| Pap smear | 0.380615 |
| following PDQ summaries | 0.395466 |
| Cancer Information Service | 0.388041 |
| human papillomavirus | 0.366703 |
| PDQ cancer information | 0.504059 |
| false-negative test result | 0.373852 |
| Prevention Editorial Board | 0.401875 |
| National Cancer Institute | 0.462131 |
| clinical trials | 0.549883 |
| cervical changes | 0.387237 |
| Pap tests | 0.380549 |
| false-positive test results | 0.375133 |
|
| cancer information summary | 0.450393 |
| Pap test | 0.755213 |
| cervix | 0.421409 |
| positive Pap test | 0.475496 |
| breast cancer prevention | 0.377745 |
| Cancer screening trials | 0.426144 |
| HPV test | 0.524062 |
| cervical cancer screening | 0.546179 |
| Cancer Care page | 0.38052 |
| cervical cancer | 0.937005 |
| PDQ summary | 0.376855 |
| HPV DNA test | 0.398682 |
| cervical tissue | 0.390487 |
| cancer symptoms | 0.370983 |
| NCI PDQ cancer | 0.416761 |
| HPV infection | 0.382279 |
| cells | 0.465881 |
| tests | 0.403289 |
| cancer information summaries | 0.392344 |
| cervical dysplasia | 0.41859 |
| comprehensive cancer information | 0.393061 |
| HPV infections | 0.396784 |
| women | 0.413929 |
|
CLICK HERE |
| 1690 |
National Cancer Institute |
Html |
en |
Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of pheochromocytoma and paraganglioma. |
| cancer treatment | 0.520384 |
| malignant tumor cells | 0.51392 |
| inherited pheochromocytoma | 0.499674 |
| metastatic pheochromocytoma | 0.559666 |
| catecholamine levels | 0.546812 |
| recurrent pheochromocytoma | 0.523941 |
| body | 0.55921 |
| PDQ cancer information | 0.583541 |
| clinical trial search | 0.545652 |
| clinical trials | 0.955841 |
| adrenal gland | 0.817016 |
| cancer information summary | 0.547255 |
| clinical trial | 0.684878 |
| blood pressure | 0.689096 |
| entire adrenal gland | 0.501423 |
| detailed pictures | 0.500985 |
| patients | 0.570303 |
| pheochromocytoma | 0.843137 |
| blood vessels | 0.513601 |
| PDQ Pheochromocytoma | 0.514265 |
| NCI PDQ cancer | 0.498564 |
| lymph nodes | 0.51055 |
| radiation therapy | 0.504762 |
| tyrosine kinase inhibitor | 0.539116 |
|
| benign pheochromocytoma | 0.496121 |
| treatment | 0.708415 |
| general information | 0.506946 |
| magnetic resonance imaging | 0.497402 |
| cancer cells | 0.57041 |
| adrenal cortex | 0.501382 |
| adrenal medulla | 0.501576 |
| multiple endocrine neoplasia | 0.503339 |
| treatment clinical trials | 0.532049 |
| National Cancer Institute | 0.548616 |
| tumor cells | 0.524483 |
| new treatment | 0.564593 |
| heart rate | 0.509798 |
| pheochromocytoma spreads | 0.501294 |
| pheochromocytoma cells | 0.532172 |
| Pheochromocytoma forms | 0.519073 |
| adrenal glands | 0.85433 |
| nuclear magnetic resonance | 0.499251 |
| paraganglioma | 0.578972 |
| tumors | 0.523973 |
| cancer clinical trials | 0.561663 |
| high blood pressure | 0.675166 |
| tumor | 0.650897 |
| cancer | 0.88724 |
|
CLICK HERE |
| 1940 |
National Cancer Institute |
Html |
es |
La espiritualidad en el tratamiento del cáncer (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca de la influencia que tiene la espiritualidad y la religión en las personas que tienen cáncer. Se discuten varios métodos sobre manejo e intervención. |
| enfermos ayuda | 0.452293 |
| La espiritualidad | 0.924579 |
| términos espiritualidad | 0.486044 |
| siguientes aspectos | 0.444194 |
| Physician Data Query | 0.534722 |
|
| National Cancer Institute | 0.427034 |
| siguientes riesgos | 0.41834 |
| libre uso | 0.416111 |
| siguientes maneras | 0.524006 |
| Instituto Nacional | 0.45946 |
|
CLICK HERE |
| 2073 |
National Cancer Institute |
Html |
es |
Biopsia de ganglio linfático centinela |
Describe el procedimiento de biopsia de ganglio linfático centinela, su uso para determinar la extensión, o estadio, del cáncer en el cuerpo, y los resultados de investigación sobre el uso de este tipo de biopsia en cáncer de seno y melanoma. |
| Surgical Adjuvant Breast | 0.600625 |
| Lancet Oncology | 0.600394 |
| falsa sensación | 0.600322 |
| American Medical Association | 0.600457 |
| Hunt KK | 0.600275 |
| excelente resultado | 0.600374 |
| Anderson SJ | 0.600281 |
| ganglio linfático centinela | 0.999164 |
| Selective Lymphadenectomy Trial | 0.600594 |
| Bowel Project | 0.600314 |
| células inmunitarias llamadas | 0.601282 |
| Julian TB | 0.600295 |
| Ballman KV | 0.60032 |
| linfocitos b | 0.600438 |
| Giuliano AE | 0.600304 |
| rara vez | 0.60032 |
| ganglios linfáticos centinelas | 0.613287 |
| sentinel node metastasis | 0.600629 |
| axillary dissection | 0.600834 |
| Instituto Nacional | 0.602213 |
|
| Krag DN | 0.600307 |
| Lyman GH | 0.600292 |
| Axillary dissection vs | 0.600551 |
| fase iii | 0.601556 |
| Surgeons Oncology Group | 0.600619 |
| ganglio centinela | 0.636993 |
| ecografÃa rutinaria | 0.600317 |
| pequeña incisión | 0.600338 |
| overall survival findings | 0.600577 |
| PubMed Abstract | 0.601839 |
| sentinel lymph | 0.601172 |
| Silbermins D | 0.600275 |
| with invasive breast | 0.600626 |
| Lymphatic mapping | 0.600313 |
| patients with | 0.600887 |
| linfadenectomÃa axilar | 0.605014 |
| Instituto Oncológico John | 0.60052 |
| Clinical Oncology | 0.600393 |
| NSABP B-32 | 0.600293 |
|
CLICK HERE |
| 3712 |
National Cancer Institute |
Html |
en |
Understanding Precision Medicine in Cancer Treatment |
Precision medicine helps doctors select cancer treatments that are most likely to help patients based on a genetic understanding of their disease. Learn about the promise of precision medicine and the role it plays in cancer treatment. |
| cancer treatment | 0.440203 |
| routine care | 0.360336 |
| tumor profiling | 0.359671 |
| medicine clinical trials | 0.414587 |
| type | 0.382285 |
| specific change | 0.357217 |
| new treatments | 0.362099 |
| treatments | 0.484331 |
| research | 0.393932 |
| open trials | 0.357639 |
| rectal cancers | 0.362107 |
| Targeted Cancer Therapies | 0.436947 |
| clinical trials | 0.515013 |
| cancer-causing genetic changes | 0.439486 |
| precision medicine approach | 0.418811 |
| additional genetic changes | 0.428246 |
| cancer-causing changes | 0.378722 |
| researchers | 0.363172 |
| patients | 0.398147 |
| trial staff | 0.356601 |
| cancer types | 0.375159 |
| patient care | 0.366351 |
| different types | 0.361116 |
| Tumor DNA Sequencing | 0.40382 |
| radiation therapy | 0.360769 |
|
| precision medicine | 0.96121 |
| person’s cancer | 0.378533 |
| genetic tests | 0.37503 |
| treatment | 0.491183 |
| precision medicine trials | 0.417382 |
| United States | 0.359831 |
| Cancer Information Service | 0.419259 |
| special lab | 0.36045 |
| targeted drug | 0.368994 |
| genetic understanding | 0.381915 |
| consent form | 0.358985 |
| different people | 0.367337 |
| Research studies | 0.361413 |
| molecular profiling | 0.357183 |
| drugs | 0.382294 |
| specific genetic changes | 0.430567 |
| certain genetic changes | 0.427035 |
| Targeted Therapy | 0.372422 |
| recent advances | 0.370536 |
| genetic changes | 0.967087 |
| specific types | 0.356978 |
| medicine clinical trial | 0.490589 |
| search tool | 0.359567 |
| cancer | 0.783975 |
|
CLICK HERE |
| 16567 |
National Cancer Institute |
Html |
en |
Pembrolizumab Improves Survival for Some Patients with Advanced Non-Small Cell Lung Cancer |
A summary of clinical trial results showing that pembrolizumab improved progression-free and overall survival for patients with advanced non-small cell lung cancer. |
| platinum-based chemotherapy | 0.628936 |
| PD-L1 positive tumors | 0.620887 |
| advanced non-small cell | 0.629259 |
| PD-L1 expression | 0.628117 |
| 1-year overall survival | 0.61848 |
| higher progression-free survival | 0.617259 |
| chemotherapy | 0.698592 |
| time patients | 0.588415 |
| chemotherapy group | 0.668963 |
| immune-mediated adverse events | 0.635601 |
| Dana-Farber Cancer Institute | 0.607312 |
| lung cancer | 0.570765 |
| biomarker. Earlier trials | 0.611797 |
| PD-L1 IHC 22C3 | 0.643265 |
| immune response | 0.572023 |
| PD-L1 protein present | 0.63991 |
| overall survival | 0.629887 |
| immune-mediated deaths | 0.578857 |
| National Cancer Institute | 0.604313 |
| tumor cells | 0.913581 |
| randomized phase | 0.574689 |
| median progression-free survival | 0.633329 |
| PD-L1-expressing tumor cells | 0.661448 |
| immune therapy | 0.577956 |
|
| immune-mediated events | 0.578589 |
| progression-free survival | 0.757999 |
| pembrolizumab group | 0.672943 |
| platinum-based doublet chemotherapy | 0.672126 |
| standard chemotherapy | 0.609699 |
| phase III CheckMate | 0.569846 |
| patients | 0.63251 |
| trial results | 0.620704 |
| previously treated patients | 0.61738 |
| immune cells | 0.61252 |
| adverse events | 0.670445 |
| Dr. Malik | 0.709776 |
| earlier phase trial | 0.627214 |
| metastatic NSCLC | 0.599852 |
| Bruce E. Johnson | 0.59961 |
| survival advantage | 0.568599 |
| untreated advanced NSCLC | 0.642891 |
| New England Journal | 0.615224 |
| severe skin reactions | 0.605442 |
| checkpoint inhibitor pembrolizumab | 0.658193 |
| phase III trial | 0.569107 |
| Pembrolizumab blocks PD-1 | 0.629649 |
| Shakun Malik | 0.582607 |
|
CLICK HERE |